MAPT and Alzheimer disease: In this study, we analyzed non-demented Alzheimer's Disease Neuroimaging Initiative (ADNI) participants who had concurrent (within 1 year) CSF Aβ42/Aβ40, phosphorylated tau (p-Tau), Aβ PET and tau PET data and divided them into four different CSF/PET amyloidosis stages based on the abnormal status of CSF Aβ42/Aβ40 and Aβ PET.